Mirna Therapeutics, Inc.Announces First Patient Enrolled In Hematological Malignancy Cohort Of Its Phase 1 Clinical Trial
6/10/2014 10:00:16 AM
AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc. (Mirna), a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company’s lead product candidate and first microRNA mimic in human clinical trials in oncology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by